Li Ling-Lin, Yuan Hong-Ling, Yang Yu-Qiong, Wang Lin, Zou Ren-Chao
Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Kunming Medical University, Kunming, 650101, Yunnan, China.
Department of Nephrology, The First Affiliated Hospital of Kunming Medical University, Kunming 650032, Yunnan, China.
J Cancer. 2020 Jul 11;11(18):5424-5431. doi: 10.7150/jca.46308. eCollection 2020.
The understanding concerning the function of immune system in cancer has achieved considerable advance with time passes by. Manipulating genetically engineered immune cells were investigated as a novel strategy for treating cancer. Chimeric antigen receptors (CARs) are recombinant protein molecules by merging the exquisite targeting the potent cytotoxicity of T cells and specificity of monoclonal antibodies and, which could trigger serial cascades of signal transduction and thereby activate T cells to directly destroy the tumor cells. Manufacturing CAR-modified T lymphocytes were successfully implemented in treating cancer derived from they could specifically retarget tumor-associated antigens, causing effective elimination of tumor cells, which spurred the optimization and development of new CAR-T cell technology. The advancement of synthetic biology methodologies of cell therapy in CAR-T would ultimately provide us with a much safer, reliable and efficient modality to against cancer. This review primarily described the emergence, development and application of cell therapy in CAR-T, then discuss the side effects and the potential factors of tumor reccurrence caused by CAR-T cell therapy, in addition to the corresponding countermeasure concerning complications.
随着时间的推移,关于免疫系统在癌症中的作用的认识取得了长足的进展。对基因工程改造的免疫细胞进行操控作为一种治疗癌症的新策略受到了研究。嵌合抗原受体(CARs)是通过将T细胞强大的细胞毒性的精准靶向与单克隆抗体的特异性相结合而形成的重组蛋白分子,其能够触发一系列信号转导级联反应,从而激活T细胞直接摧毁肿瘤细胞。制造CAR修饰的T淋巴细胞已成功应用于癌症治疗,因为它们可以特异性地重新靶向肿瘤相关抗原,有效清除肿瘤细胞,这推动了新型CAR-T细胞技术的优化和发展。CAR-T细胞疗法中细胞治疗的合成生物学方法的进步最终将为我们提供一种更安全、可靠和有效的抗癌方式。本综述主要描述了CAR-T细胞疗法中细胞治疗的出现、发展和应用,然后讨论了CAR-T细胞疗法引起的副作用和肿瘤复发的潜在因素,以及针对并发症的相应对策。
J Cancer. 2020-7-11
Hepatobiliary Pancreat Dis Int. 2018-5-24
Acta Naturae. 2017
Cancers (Basel). 2021-1-22
Cell Commun Signal. 2020-8-25
Mol Ther. 2017-7-20
Eur J Immunol. 2021-9
Cancer Immunol Immunother. 2019-8-14
Vaccines (Basel). 2021-10-25
J Clin Invest. 2020-6-1
Clin Cancer Res. 2019-5-20
Trends Cell Biol. 2019-2-11
Onco Targets Ther. 2018-10-4
Front Immunol. 2018-7-27
Front Immunol. 2018-7-30
Front Immunol. 2018-6-29